Experimental Ebola Vaccinations to Resume in Democratic Republic of Congo

In response to a new outbreak, health workers will start administering vaccines again soon.

Written byAshley Yeager
| 2 min read
Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

Health workers in eastern Democratic Republic of Congo (DRC) will begin administering vaccinations against a new outbreak of Ebola virus starting Wednesday (August 8), Reuters reports.

The vaccine is experimental, but was used on a wide scale to combat the outbreak in northwestern Congo that was declared over two weeks again (July 24). Still, thousands of doses remain in the country’s capital, Kinshasa. Using the remaining vaccine doses in the new outbreak is “common sense,” a DRC Ministry of Public Health spokesperson tells ScienceInsider, because both scientific and ethical committees have already given the go ahead to continue to study the effectiveness of the vaccine. In the earlier outbreak, preliminary data indicate that 3,300 individuals were vaccinated and none of them became infected with Ebola, ScienceInsider reports.

The current outbreak is in the North Kivu region, on the opposite side of DRC from the last outbreak. Barthe Ndjoloko, who oversees ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • Ashley started at The Scientist in 2018. Before joining the staff, she worked as a freelance editor and writer, a writer at the Simons Foundation, and a web producer at Science News, among other positions. She holds a bachelor’s degree in journalism from the University of Tennessee, Knoxville, and a master’s degree in science writing from MIT. Ashley edits the Scientist to Watch and Profile sections of the magazine and writes news, features, and other stories for both online and print.

    View Full Profile
Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies